Vericel’s MACI Arthro to Drive Growth for Years
The company's MACI revenues grew nearly 25% in 2023 and Vericel expects the launch of MACI Arthro in the third...
The company's MACI revenues grew nearly 25% in 2023 and Vericel expects the launch of MACI Arthro in the third...
The company grew more than 37% in 2023 as its procedural solutions win over surgeons in a disrupted spine market....
The company grew more than 30% in 2023 and added another $750 million to its already massive $5 billion total...
The company's orthopedic sales grew in the mid-single-digits for 2023 but were hamstrung by supply constraints and headwinds in China....
The company's orthopedic sales grew in the mid-teens for 2023 and is likely to be a $1 billion recon player...
The company finished 2023 with reported sales growth over 50% as it works to integrate NuVasive and reach a steady...
Healthy end markets and a robust innovation pipeline drove mid-single-digit growth for the company in 2023....
The company grew in the mid-teens for 2023 but can't fully go on offense until it resolves its supply chain...
The company's orthopedic sales grew nearly 10% in 2023, driven by strong procedure demand, leadership in robotics and momentum in...
The company grew in the mid-single-digits in 2023 as new products and recovering markets fueled its rebound to pre-COVID levels....
As a guest member you get access to more articles and webinars every month.
We’ll send a recovery link to your email.
Return to Homepage